Apollomics Inc. Class A Ordinary Shares
Symbol: APLM (NASDAQ)
6.14
▼ (-0.89%) -0.055
Company Description:
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Key Stats
- Today's Open: $6.26
- Today's High: $6.399
- Today's Low: $5.591
- Today's Volume: 24.60K
- Yesterday Close: $6.19
- Yesterday High: $6.25
- Yesterday Low: $5.75
- Yesterday Volume: 7.54K
- Last Min Volume: 1
- Last Min High: $6.135
- Last Min Low: $6.135
- Last Min VWAP: $6.135
Company Profile
- Name: Apollomics Inc. Class A Ordinary Shares
- Website: https://www.apollomicsinc.com
- Listed Date: 2023-03-30
- Location: ,
- Market Status: Active
- CIK Number: 0001944885
- SIC Code:
- SIC description:
- Market Cap: $13.27M
- Round Lot: 100
- Outstanding Shares: 2.14M
- Asset Type: CS
RECENT FILINGS FOR APLM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | SCHEDULE 13D | View |
| 2025-09-05 | SCHEDULE 13G/A | View |
| 2025-09-05 | 6-K | View |
| 2025-09-03 | 6-K | View |
| 2025-08-28 | 6-K | View |
| 2025-07-25 | 6-K | View |
| 2025-04-03 | 20-F | View |
| 2025-04-03 | 6-K | View |
| 2025-03-31 | 6-K | View |
| 2025-01-10 | SCHEDULE 13G/A | View |
| 2024-12-20 | 6-K | View |
| 2024-12-10 | 6-K | View |
| 2024-11-14 | 6-K | View |
| 2024-11-01 | 6-K | View |
| 2024-08-15 | SC 13D/A | View |
| 2024-08-14 | 6-K | View |
| 2024-08-01 | 6-K | View |
| 2024-07-16 | 6-K | View |
| 2024-07-03 | 6-K | View |
| 2024-05-30 | SC 13G/A | View |
Latest News on APLM